227 related articles for article (PubMed ID: 23424667)
21. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.
Stoffers DA; Desai BM; DeLeon DD; Simmons RA
Diabetes; 2003 Mar; 52(3):734-40. PubMed ID: 12606515
[TBL] [Abstract][Full Text] [Related]
22. Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.
Fan R; Kang Z; He L; Chan J; Xu G
PLoS One; 2011; 6(5):e20443. PubMed ID: 21655268
[TBL] [Abstract][Full Text] [Related]
23. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
24. Maternofetal inflammation induced for 2 wk in late gestation reduced birth weight and impaired neonatal growth and skeletal muscle glucose metabolism in lambs.
Posont RJ; Cadaret CN; Beard JK; Swanson RM; Gibbs RL; Marks-Nelson ES; Petersen JL; Yates DT
J Anim Sci; 2021 May; 99(5):. PubMed ID: 33780540
[TBL] [Abstract][Full Text] [Related]
25. Chronically Increased Amino Acids Improve Insulin Secretion, Pancreatic Vascularity, and Islet Size in Growth-Restricted Fetal Sheep.
Brown LD; Davis M; Wai S; Wesolowski SR; Hay WW; Limesand SW; Rozance PJ
Endocrinology; 2016 Oct; 157(10):3788-3799. PubMed ID: 27501184
[TBL] [Abstract][Full Text] [Related]
26. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
27. Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat.
Pinney SE; Jaeckle Santos LJ; Han Y; Stoffers DA; Simmons RA
Diabetologia; 2011 Oct; 54(10):2606-14. PubMed ID: 21779870
[TBL] [Abstract][Full Text] [Related]
28. Intrauterine growth retardation leads to the development of type 2 diabetes in the rat.
Simmons RA; Templeton LJ; Gertz SJ
Diabetes; 2001 Oct; 50(10):2279-86. PubMed ID: 11574409
[TBL] [Abstract][Full Text] [Related]
29. Effects of birth weight and dietary fat on intake, body composition, and plasma thyroxine in neonatal lambs.
Ramos-Nieves JM; Giesy SL; McGuckin MM; Boisclair YR
J Anim Sci; 2020 Dec; 98(12):. PubMed ID: 33196782
[TBL] [Abstract][Full Text] [Related]
30. In vivo biological activity of exendin (1-30).
Doyle ME; McConville P; Theodorakis MJ; Goetschkes MM; Bernier M; Spencer RG; Holloway HW; Greig NH; Egan JM
Endocrine; 2005 Jun; 27(1):1-9. PubMed ID: 16077164
[TBL] [Abstract][Full Text] [Related]
31. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
32. Intrauterine growth retardation leads to the functional change of insulin secretion in the newborn rats.
Yuan QX; Zhou JY; Teng LP; Liu CP; Guo J; Liu LJ; De W; Xu KF; Mao XD; Liu C
Horm Metab Res; 2010 Jun; 42(7):491-5. PubMed ID: 20225168
[TBL] [Abstract][Full Text] [Related]
33. A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo.
Kitani K; Oguma S; Nishiki T; Ohmori I; Galons H; Matsui H; Meijer L; Tomizawa K
J Physiol Sci; 2007 Aug; 57(4):235-9. PubMed ID: 17854513
[TBL] [Abstract][Full Text] [Related]
34. Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.
Juang JH; Kuo CH; Wu CH; Juang C
Cell Transplant; 2008; 17(6):641-7. PubMed ID: 18819252
[TBL] [Abstract][Full Text] [Related]
35. Antenatal blockade of N-methyl-D-aspartate receptors by Memantine reduces the susceptibility to diabetes induced by a high-fat diet in rats with intrauterine growth restriction.
Huang XT; Yue SJ; Li C; Guo J; Huang YH; Han JZ; Feng DD; Luo ZQ
Biol Reprod; 2017 May; 96(5):960-970. PubMed ID: 28486599
[TBL] [Abstract][Full Text] [Related]
36. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.
Wei Q; Sun YQ; Zhang J
Peptides; 2012 Sep; 37(1):18-24. PubMed ID: 22776329
[TBL] [Abstract][Full Text] [Related]
37. Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas.
Egido EM; Silvestre RA; Hernández R; Marco J
Horm Metab Res; 2004 Sep; 36(9):595-600. PubMed ID: 15486809
[TBL] [Abstract][Full Text] [Related]
38. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
39. High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells.
Li H; Lam A; Xu AM; Lam KS; Chung SK
Acta Pharmacol Sin; 2010 May; 31(5):570-7. PubMed ID: 20418895
[TBL] [Abstract][Full Text] [Related]
40. Placental restriction of fetal growth increases insulin action, growth, and adiposity in the young lamb.
De Blasio MJ; Gatford KL; McMillen IC; Robinson JS; Owens JA
Endocrinology; 2007 Mar; 148(3):1350-8. PubMed ID: 17110432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
